SYLENTIS
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and ce... ntral nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company
SYLENTIS
Social Links:
Industry:
Biotechnology
Founded:
2006-01-01
Address:
Madrid, Madrid, Spain
Country:
Spain
Website Url:
http://www.sylentis.com
Total Employee:
11+
Status:
Active
Contact:
34 91 804 7667
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving Google Tag Manager Euro Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps Content Delivery Network
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Neumedicines
Neumedicines is a biotechnology company that focuses on the development of protein therapeutics.
Xenova
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Current Employees Featured
Founder
Official Site Inspections
http://www.sylentis.com Semrush global rank: 8.56 M Semrush visits lastest month: 624
- Host name: ns50251.webempresa.eu
- IP address: 213.158.84.20
- Location: Italy
- Latitude: 43.1479
- Longitude: 12.1097
- Timezone: Europe/Rome
More informations about "SYLENTIS"
About Sylentis – Sylentis
Sylentis holds a Certificate of Compliance with Good Manufacturing Practices from the Spanish Agency for Medicines and Health Products. Polígono Industrial Los Olivos Calle Progreso Nº3, …See details»
Sylentis – RNAi Biopharmaceuticals
Sylentis rationally designs drugs that specifically interfere with the expression process of these proteins. + info. R&D&I for eye health. Sylentis’ most advanced developments are focused on the ophthalmological area. Dry eye syndrome, …See details»
SYLENTIS - Crunchbase Company Profile & Funding
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business …See details»
SYLENTIS - LinkedIn
SYLENTIS | 6,812 followers on LinkedIn. Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our ...See details»
SYLENTIS: Contact Details and Business Profile - RocketReach
Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a …See details»
Sylentis – Oligofastx
Sylentis, coordinator of the OLIGOFASTX project, is a PharmaMar Group company and one of the pioneers in the development of drugs based on RNA interference (RNAi) technology. Sylentis seeks to build a solid and sustainable …See details»
Sylentis - 2025 Company Profile, Funding
Apr 28, 2025 Sylentis is a funded company based in Tres Cantos (Spain), founded in 2006 by Jose María Fernandez Sousa Faro. It operates as a Developer of siRNA-based formulations for the treatment of eye diseases. …See details»
Sylentis Company Profile - Office Locations, Competitors ... - Craft
Sylentis is a biotechnology company focused on the development of ophthalmic drugs and therapies based on RNAi (gene silencing) technology. It serves patients with dry eye, retina …See details»
Sylentis | AseBio - Asociación Empresas Biotecnología
Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia. Areas of interest for future collaborations Because …See details»
Sylentis S.A. - BioCentury Company Profiles - BCIQ
Oct 4, 2021 Sylentis S.A. - BioCentury Company Profiles for the biopharma industrySee details»
SYLENTIS - Contacts, Employees, Board Members, Advisors & Alumni
Organization. SYLENTIS . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. SYLENTIS has 2 current …See details»
Sylentis - Overview, News & Similar companies | ZoomInfo.com
Who is Sylentis. Sylentis is a PharmaMar Group pharmaceutical company focused on the discovery and development of innovative therapies based on gene silencing techn ologies or …See details»
Clinical trials - Sylentis
You can consult the clinical trials of which Sylentis is a sponsor HERE. Polígono Industrial Los Olivos Calle Progreso Nº3, 28906 Getafe, Spain +34 91 804 76 67 [email protected]. About …See details»
Sylentis SA - Drug pipelines, Patents, Clinical trials - Synapse
Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with …See details»
SYOLIGO - Syoligo, a Sylentis project
Sylentis participates as IPCEI direct partner. Vision Sylentis, with the SYOLIGO project, seeks to promote new therapeutic approaches with RNA oligonucleotides aimed at rare diseases and to …See details»
Sylentis - VentureRadar
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new …See details»
Sylentis - VentureRadar
Similar Companies: Silence Therapeutics United Kingdom Publicly Traded Silence Therapeutics is developing a new generation of medicines by harnessing the body’s naturalmechanism of …See details»
Careers – Sylentis
Sylentis believes in its people. We are committed to our employees and actively promote the principles of progress and innovation in the healthcare sector. We focus on developing talent …See details»
Delving into the Latest Updates on Sylentis SA with Synapse
5 days ago 了解Sylentis SA (Sylentis SA)公司的药物管线，治疗领域，技术平台，以及它的16项临床试验, 29篇新闻，疾病领域:免疫系统疾病，技术平台:siRNA，药物:Tivanisiran，SYL …See details»
Sylentis, a PharmaMar Group company, announces the positive …
SYL1801 is a novel siRNA targeting the notch-regulated ankyrin repeat protein (NRARP). The results of this study support further investigation of SYL1801 and pave the way for the next stage of clinical development, bringing Sylentis one step closer to offering a new therapeutic option for patients affected with retinal diseases worldwide.See details»